COMMON MAPS
Map version new-york activity top-down
Main site Contact
Menu
↑ parent activity group ·
research dossier

GYNUITY HEALTH PROJECTS INC
NEW YORK, NY · EIN 825129481 · Form 990 · FY2024 · NTEE E40 · Health Care · Small ($100K-$1M) · gynuity.org
revenue
$830K
expenses
$936K
net assets
$75K
employees
6
volunteers
6
program ratio
53%
mission · from form 990

GYNUITY'S APPROACH STARTS AT THE COMMUNITY LEVEL WHERE WE LISTEN TO WOMEN, PROVIDERS AND POLICYMAKERS, AND WORK WITH THEM TO CREATE SERVICES THAT ARE SAFE, OF HIGH QUALITY AND MORE PERSON-CENTERED. THROUGH CONVERSATIONS AND ACTIVE COLLABORATIONS WITH PARTNERS ON-THE GROUND, WE FILL EVIDENCE GAPS BY USING BASIC SCIENCE RESEARCH, CLINICAL RESEARCH, IMPLEMENTATION RESEARCH TO ACHIEVE PROOF OF CONCEPT FOR NEW MODELS OF CARE. WE USE THIS INFORMATION TO INFLUENCE CHANGE AND ADVOCATE FOR IMPROVEMENTS IN POLICY AND PRACTICE.

profile · synthesized from sources

Gynuity Health Projects is a research and advocacy organization focused on improving women's reproductive health through evidence-based innovations in abortion and maternal care. The organization conducts clinical and implementation research to develop and promote safe, high-quality, person-centered models of care. It works globally to influence policy and practice by generating scientific evidence and engaging with providers, policymakers, and communities.

named programs · 5 · from sources

What they call their work

Abortion Policy and Access Research
Analysis of legal, policy, and structural barriers to abortion access, including studies on abortion bans and escort policies.
Medication Abortion Without Ultrasound
Studies assessing the safety and effectiveness of medication abortion without routine pretreatment ultrasound or pelvic examination.
Person-Centered Maternal Care
Development and validation of tools like the Participant-Generated Experience and Satisfaction (PaGES) Index to measure patient experience in labor induction and maternal care.
Postpartum Hemorrhage Management
Research on clinical markers, interventions, and community-based approaches to prevent and manage postpartum hemorrhage in low-resource settings.
Telemedicine Medical Abortion
Research and evaluation of telemedicine models for medication abortion, including no-test and direct-to-patient protocols in the U.S. and globally.
activities · 4 groups

What they do

  • Reproductive Health Access and Support Services 2 activities
    • Advancing telemedicine models for abortion care
      Conducts research on telemedicine abortion services, including the TelAbortion study, which provides medication abortion via videoconference and mailed medications, and evaluates no-test protocols that omit routine ultrasound or pelvic exams. Studies assess safety, feasibility, and acceptability in the U.S. and internationally, including Ukraine, Uzbekistan, Azerbaijan, and Mexico.
    • Conducting reproductive health implementation research in low-resource settings
      Conducts clinical and operational research in countries including Nepal, Myanmar, Senegal, and Niger to evaluate and scale evidence-based practices such as outpatient medical induction, misoprostol for incomplete abortion, and task-sharing in maternal and reproductive health care. Includes training, guideline development, and dissemination of findings.
  • Reproductive Health Advocacy & Education 2 activities
    • Advocating for evidence-based reproductive health policies and practices
      Uses research findings to influence national and international policy and clinical practice, including contributing to updated protocols at Planned Parenthood Federation of America and the Mexican Ministry of Health on contraceptive timing after abortion, and organizing expert forums to disseminate technical updates on reproductive health topics.
    • Researching and mapping global access to abortion medications
      Tracks and maps global approvals of mifepristone and conducts landscape assessments on regulatory and market pathways for new reproductive health technologies, including on-demand oral contraceptives. Collaborates with PATH, WHO, and other partners to identify optimal approval pathways and research needs.
  • Medical Research & Education Dissemination 1 activity
    • Developing and disseminating educational resources for reproductive health
      Creates and distributes multilingual research summaries, FAQs, issue briefs, and training materials for policymakers, health providers, and organizations. Includes development of a one-day training course on task-sharing in maternal and reproductive health based on a compendium of evidence-based practices.
  • Uncategorized 4 activities
    • Conducting clinical and implementation research on medication abortion regimens
      Conducts proof-of-concept studies, randomized controlled trials, and systematic reviews to evaluate the safety, efficacy, and acceptability of medication abortion regimens, including those using ulipristal acetate, misoprostol-only, and alternative drugs like letrozole. Research spans multiple countries and includes regimens for early abortion and treatment of early missed menses, with findings contributing to clinical guidelines and regulatory decisions.
    • Conducting global individual participant data meta-analyses on maternal health
      Collaborates with WHO on individual participant data meta-analyses to assess the prognostic accuracy of clinical markers in predicting maternal mortality or severe morbidity from postpartum bleeding, generating high-level evidence to inform global maternal health guidelines and interventions.
    • Conducting maternal health research on hypertensive disorders in pregnancy
      Conducts clinical trials and landscape assessments on the management of hypertensive disorders in pregnancy, including comparative efficacy of antihypertensive drugs (labetalol, nifedipine, methyldopa), use of oral misoprostol for labor induction, and improved magnesium sulfate delivery methods such as the Springfusor® pump and serial IV boluses. Research is conducted in India, Egypt, Mexico, and Bangladesh.
    • Generating evidence on postpartum hemorrhage prevention and treatment
      Conducts clinical trials and implementation research on the use of misoprostol and other interventions for preventing and treating postpartum hemorrhage, including studies on sublingual dosing, antenatal distribution, community education, and task-sharing with auxiliary midwives. Research spans multiple countries including Senegal, Uganda, Egypt, Pakistan, and India, and includes monitoring and evaluation of national programs.
financials · form 990 · fy2024
revenue
Total revenue$830K
Contributions & grants$821K99%
Program service revenue$2K0%
Investment income$7K1%
Other revenue$0
expenses
Total expenses$936K
Program expenses53%
Admin / overhead42%
Fundraising5%
Salaries & benefits$495K
Grants paid out$0
Largest expense lineCompensation
balance sheet
Total assets$354K
Cash$149K
Investments$0
Liabilities$278K
Net assets$75K
Liquid reserves1.9 mo
3 years on record · 2020–2024 · YoY revenue +72.5%
leadership · form 990 part vii · fy2024

Who runs it

paid leadership · 3
NameTitleHours/wkCompensation
BEVERLY WINIKOFF PRESIDENT 35 $184K
YELENA ELYUKIN TREASURER/SR. DIR. OF FINANCE AND ADMINISTRATION 35 $103K
JILL DUROCHER INTERIM SECRETARY/SENIOR DIRECTOR 25 $76K
board members · 6
  • ANJU MALHOTRA — DIRECTOR (THRU APRIL)
  • ANN SCHUTT-AINE — DIRECTOR
  • BARBARA CRANE — DIRECTOR
  • GEORGE BROWN — CHAIR
  • PAMELA BARNES — DIRECTOR (THRU JAN)
  • SILVINA RAMOS — DIRECTOR
relationships · 29

Who they work with

  • Centers for Disease Control and Prevention Partner — Partnered with Gynuity on research into Clostridium sordellii and Clostridium perfringens in the context of medication abortion.
  • ChildFund Senegal Partner — Collaborated with Gynuity on the evaluation of the scale-up of Senegal’s national community strategy for postpartum hemorrhage prevention.
  • Comunidad de Partería en México Partner — Participates in a virtual community of practice to strengthen midwifery in Mexico by sharing evidence-based resources and training materials.
  • Daga Memorial Women’s Hospital Partner — Partnered in a randomized trial on oral anti-hypertensive regimens for severe hypertension in pregnancy.
  • Duke University Partner — Contributed expert clinical perspective on Zika virus and pregnancy outcomes through participation in a Gynuity-sponsored forum.
  • Georgian Society of Contraception and Reproductive Health Partner — Collaborated with Gynuity on initiatives to improve safe abortion access in Georgia; presented a Special Award of Recognition for contributions to the field.
  • Government Medical College, Nagpur Partner — Partnered in a randomized trial on oral anti-hypertensive regimens for severe hypertension in pregnancy.
  • Mexican Ministry of Health Government — Updated national protocols to permit administration of progestin-based contraceptives at the time of medication abortion initiation following Gynuity's clinical trial results.
  • New York City Department of Health and Mental Hygiene Partner — Participated in a Gynuity-sponsored plenary session on Zika virus and reproductive health, contributing expert insights on public health policy.
  • Orientame Foundation Partner — Provided international expertise on Zika-related reproductive health challenges in Colombia during a Gynuity-organized session.
  • PATH Partner — Collaborated with Gynuity to assess regulatory and market pathways for an on-demand oral contraceptive pill.
  • Planned Parenthood Partner — Collaborated on policy implementation based on Gynuity's research findings regarding gestational age limits for medication abortion.
  • Planned Parenthood Federation of America Government — Adopted updated protocols allowing administration of progestin-based contraceptives during the initial medication abortion visit based on Gynuity's research findings.
  • RM Alden Research Laboratory Partner — Partnered with Gynuity on studies of clostridial bacteria and antibiotic resistance in the context of medication abortion.
  • Reproductive Health Supplies Coalition Funder — Funded a landscape assessment of access to antihypertensive medicines and blood pressure devices in Uganda, Mexico, and India.
  • Reproductive Health Technologies Project Partner — Collaborated with Gynuity to assess options for bringing an on-demand oral contraceptive pill to market.
  • The Bill and Melinda Gates Foundation Funder — Provided support for Gynuity's assessment of technologies and interventions for postpartum hemorrhage care in low-resource settings.
  • U.S. Food & Drug Administration Government — FDA's regulatory decisions on mifepristone inform Gynuity's research priorities and public response.
  • University of British Columbia Partner — Collaborated on a randomized trial comparing oral anti-hypertensive drugs for severe hypertension in pregnancy.
  • University of Liverpool Partner — Collaborated on studies assessing labor induction and augmentation methods in women with preeclampsia in India.
  • University of Washington Partner — Collaborated on a randomized trial comparing oral anti-hypertensive drugs for severe hypertension in pregnancy.
  • University of Washington Partner — Collaborated with Gynuity on research related to clostridial infections, medication abortion, and antibiotic use.
  • Vanderbilt University Partner — Collaborated with Gynuity on research concerning clostridial infections and medication abortion.
  • Winikoff et al. Partner — Collaborated on a published proof-of-concept study evaluating ulipristal acetate for early medication abortion.
  • World Health Organization Partner — Collaborated on a WHO individual participant data meta-analysis on postpartum hemorrhage.
  • World Health Organization Partner — Collaborated on a meta-analysis assessing clinical markers of postpartum bleeding to predict maternal mortality or severe morbidity.
  • World Health Organization Partner — Collaborated with Gynuity to evaluate development pathways for an on-demand oral contraceptive pill.
  • partner clinics in the U.S. and Mexico Partner — Collaborating with partner clinics in the U.S. and Mexico to conduct studies on the efficacy and acceptability of period pill regimens.
  • partners on-the-ground Partner — Collaborates with local partners to conduct research and develop new models of care.
strategies · 5

How they approach the work

Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.

  • Access-Oriented Drug Development and Repurposing
    methodology: access_oriented_drug_development
    By developing or repurposing alternative medications (e.g., ulipristal acetate, misoprostol) and oral formulations for reproductive health uses, the organization improves access to safe care in restrictive or low-resource settings because these approaches bypass regulatory barriers, cold chain requirements, and dependence on specialized providers.
  • De-Medicalization and Task-Sharing in Reproductive Care
    methodology: de_medicalization_of_care
    By promoting history-based screening, telemedicine delivery, and integration of non-specialist providers like midwives and nurses, the organization expands access to abortion and maternal care because reducing unnecessary clinical requirements and broadening provider roles increases scalability and reduces cost and stigma.
  • Evidence-Based Technology Evaluation and Advocacy
    methodology: evidence_based_policy_and_practice
    By generating high-quality clinical and epidemiological research, including randomized trials and reinterpretation of existing data, the organization produces policy and practice change because rigorous evidence increases credibility and adoption among providers, policymakers, and advocates.
  • Secondary Prevention Through Targeted Clinical Protocols
    methodology: secondary_prevention_model
    By advocating for secondary prevention models—such as administering misoprostol only after identifying above-average blood loss—the organization improves maternal health outcomes because targeted interventions reduce unnecessary treatment, optimize resource use, and support sustainability in low-resource settings.
  • Woman-Controlled and Community-Appropriate Biomedical Interventions
    methodology: woman_controlled_prevention
    By designing and promoting biomedical tools that are controlled by women and adapted to community-level use (e.g., oral medications, heat-stable formulations), the organization improves reproductive health outcomes because these interventions increase autonomy, reduce reliance on health systems, and function reliably in low-resource settings.